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Breast carcinomaThe PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cell-
cancer cell interactions, defending tumor cells against immune destruction. Nano-diamino-tetrac (NDAT;
Nanotetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on
the extracellular domain of integrin avb3. NDAT inhibits the cancer cell PI3-K and MAPK signal transduc-
tion pathways that are critical to PD-L1 gene expression. We examined actions in vitro of thyroid hor-
mone (L-thyroxine, T4) and NDAT on PD-L1 mRNA abundance (qPCR) and PD-L1 protein content in
human breast cancer (MDA-MB-231) cells and colon carcinoma (HCT116 and HT-29) cells. In MDA-
MB-231 cells, a physiological concentration of T4 (107 M total; 1010 M free hormone) stimulated PD-
L1 gene expression by 38% and increased PD-L1 protein by 2.7-fold (p < 0.05, all changes). NDAT
(107 M) reduced PD-L1 in T4-exposed cells by 21% (mRNA) and 39% (protein) (p < 0.05, all changes).
In HCT116 cells, T4 enhanced PD-L1 gene expression by 17% and protein content by 24% (p < 0.05).
NDAT reduced basal PD-L1 mRNA by 35% and protein by 31% and in T4-treated cells lowered mRNA by
33% and protein by 66%. In HT-29 cells, T4 increased PD-L1 mRNA by 62% and protein by 27%. NDAT low-
ered basal and T4-stimulated responses in PD-L1 mRNA and protein by 35–40% (p < 0.05). Activation of
ERK1/2 was involved in T4-induced PD-L1 accumulation. We propose that, by a nongenomic mechanism,
endogenous T4 may clinically support activity of the defensive PD-1/PD-L1 checkpoint in tumor cells.
NDAT non-immunologically suppresses basal and T4-induced PD-L1 gene expression and protein accu-
mulation in cancer cells.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) check-
point is an essential regulator of activated T cell-tumor cell interac-
tions [1–3]. The checkpoint defends tumor cells against immune
destruction. Generated by tumor cells, PD-L1 (or B7-H1) protein
engages PD-1 to suppress activated T cell engagement with tumor
cells; the liganding may also serve to induce apoptosis of T cells.
Overexpression of PD-L1 is observed in melanoma, pancreatic
and lung cancer cells, among others, and may correlate with
decreased patient survival [1]. Antibodies directed at PD-L1 haveshown promise as immunotherapy for melanoma, lung and kidney
cancers and hematological malignancies [2,4], although clinical
activity of the antibodies appears to be limited to a minority of
each of these conditions [5–7]. Two antibodies to PD-L1 have
received limited anticancer FDA approval and additional PD-L1
antibodies are in clinical trials [3,4].
Activation of the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase (PI3-K) signal transducing pathways
is critical to expression of the PD-L1 gene in cancer cells [8,9]. The
epidermal growth factor receptor (EGFR) may drive PD-L1 expres-
sion [10] and interferon-c (IFN-c) is a potent endogenous inducer
of expression of PD-L1 [11]. Nano-diamino-tetrac (NDAT; Nanote-
trac) (Fig. 1) is an anticancer/anti-angiogenic agent directed at a
receptor for thyroid hormone and tetraiodothyroacetic acid
(tetrac) on the extracellular domain of integrin avb3 [12,13].
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Fig. 1. Structure of NDAT. Schematic diagram of the structure of Nano-diamino-
tetrac (NDAT). Tetrac is covalently bound via an ether bond involving its outer ring
hydroxyl group to a linker. The diamino-linker via an amide bond is joined to the
PLGA (poly[lactic-co-glycolic acid]) nanoparticle. Five to 8 tetrac molecules are
bound to each 150 nm nanoparticle [14].
60 H.-Y. Lin et al. / Steroids 114 (2016) 59–67Expression of the integrin is largely by cancer cells and dividing
endothelial cells, so that normal nondividing cells are very limited
targets of NDAT [12]. NDAT is made by the covalent bonding via a
linker of tetrac, a deaminated derivative of L-thyroxine (T4), to poly
(lactic-co-glycolic acid) (PLGA); this prevents cellular uptake of tet-
rac and restricts actions of the tetrac-linker molecule to the
hormone receptor on the extracellular domain of avb3 [14]. NDAT
inhibits the PI3-K and MAPK pathways in cancer cells [12,15] and
blocks expression of a panel of genes critical to cancer cell survival
pathways, and the EGFR gene [13]. Tetrac is also known to block
enhancement by thyroid hormone of actions of IFN-c [16,17].
Against this background, we studied the immune system-indepen-
dent actions of NDAT and T4 on PD-L1 expression that are initiated
at integrin avb3 in human cancer cells. T4 was studied because it is
the principal thyroid hormone ligand at the cell surface hormone
receptor on integrin avb3 [12,18].
2. Experimental methods
2.1. Cells
Human breast cancer MDA-MB-231 (ER-negative, ATCC
HTB-26TM) cells, colorectal cancer HT-29 (ATCC HTB-38TM) cells
and HCT116 (ATCC CCL-247TM) cells were obtained from American
Type Culture Collection (ATCC) (Manassas, VA, USA). These cell
lines had been tested and authenticated with BCRC (isoenzyme
analysis, Mycoplasma, cytogenetics, tumorigenesis, receptor
expression testing). Cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) (for MDA-MB-231 cells) or RPMI-1640
(for HT-29 and HCT116 cells) (Life Technologies Corp., Carlsbad,
CA, USA), supplemented with 10% FBS. Incubation conditions were
5% CO2 at 37 C. Before the study, cells were placed in 0.25% hor-
mone-depleted serum-supplemented medium for 2 days.
2.2. Quantitative real-time PCR
To examine mRNA expression, we treated HCT116 cells, HT-29
cells and MDA-MB-231 cells with vehicle, (108, 107, 106 M) T4,
107 M tetrac nanoparticle (NDAT), or combination treatments
(107 M T4, 107 M NDAT) for 24 h. Total RNA was extracted and
genomic DNA was also eliminated with Illustra RNAspin Mini
RNA Isolation Kit (GE Healthcare Life Sciences, Buckinghamshire,
UK). One lg of DNase I-treated total RNA was reverse-transcribed
with RevertAid H Minus First Strand cDNA Synthesis Kit (Life Tech-
nologies Corp.) into cDNA and used as the template for real-time
PCR reactions and analysis. The real-time PCR reactions were per-
formed using QuantiNovaTM SYBR Green PCR Kit (QIAGEN, Hilden,
Germany) on CFX ConnectTM Real-Time PCR Detection System(Bio-Rad Laboratories, Inc., Hercules, CA, USA). This involved an
initial denaturation at 95 C for 5 min, followed by 40 cycles of
denaturing at 95 C for 5 s and combined annealing/extension at
60 C for 10 s, as detailed in the manufacturer’s instructions.
The primer sequences were shown as the following: human
programmed death ligand 1 (PD-L1), forward 50-GTTGAAGGAC-
CAGCTCTCCC-30 and reverse 50-ACCCCTGCATCCTGCAATTT-30
(Accession No. AY254342.1); human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), forward 50-TGCCAAATATGATGACATCAA-
GAA-30 and reverse 50-GGAGTGGGTGTCGCTGTTG-30 (Accession No.
NM_002046). Calculations of relative gene expression (normalized
to GAPDH reference gene) were performed according to the DDCT
method. Fidelity of the PCR reaction was determined with melting
temperature analysis.
2.3. Western blotting
To examine the effects of NDAT on T4-enhanced PD-L1 expres-
sion, we performed western blot analysis to quantify the protein
expression levels of PD-L1 and the activation of ERK1/2 in the total
cell lysates of HCT116, HT-29 and MDA-MB-231 cells that had been
treated with vehicle, with (108, 107, 106 M) T4, with 107 M
NDAT, or with combined treatments (107 M T4, 107 M NDAT)
for 24 h. Protein samples were resolved on a 10% sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE). A 20-lg quantity of pro-
tein was loaded in each well with 5 sample buffer and the sam-
ples were resolved with electrophoresis at 100 V for 2 h. The
resolved proteins were transferred from the polyacrylamide gel
to Millipore Immobilon-PSQ Transfer PVDF membranes (Millipore,
Billerica, MA, USA) with the Mini Trans-Blot Cell (Bio-Rad Labora-
tories, Inc.). Membranes were blocked with a solution of 2% BSA
(bovine serum albumin) in Tris-buffered saline and incubated with
primary antibodies to PD-L1, phospho-p44/42 MAPK (pERK1/2)
(Cell Signaling Technology, Inc., Beverly, MA, U.S.A.), ERK2 and
GAPDH (GeneTex International Corp., Hsinchu City, Taiwan) at
4 C overnight and washed, and the proteins were detected with
HRP-conjugated secondary antibodies and ImmobilonTM Western
HRP Substrate Luminol Reagent (Millipore). Western blots were
visualized and recorded with the BioSpectrum Imaging System
(UVP, LLC, Upland, CA, USA). Densitometric analyses of western
blots were by ImageJ 147 software (NIH, USA).
2.4. Statistical analysis
Immunoblot and nucleotide densities were compared by IBM
SPSS Statistics software, version 19.0 (SPSS Inc., Chicago, IL USA).
Two-tailed Student’s t-test determined significance, with p values
<0.05 (*, # or §), <0.01 (**, ## or §§) and <0.001 (***, ### or §§§).3. Results
3.1. Thyroid hormone induces PD-L1 expression that is inhibited by
Nano-diamino-tetrac (NDAT) in human breast cancer MDA-MB-231
cells
Triple-negative human breast carcinoma MDA-MB-231 cells
were treated with different concentrations of T4 (108 to 106 M)
for 24 h and cells were harvested and total RNA was extracted.
The concentration of 107 M T4 yields a physiological free hormone
concentration [19]. qPCR of PD-L1 revealed that PD-L1 mRNA was
significantly induced by thyroid hormone on a concentration-
dependent basis and the increase was 38% at 107 M (Fig. 2A).
When MDA-MB-231 cells were treated with 107 M T4 in the pres-
ence of NDAT (107 M) for 24 h, the expression of PD-L1was inhib-
ited significantly by NDAT (21%) (Fig. 2B). NDAT induced a small
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MDA-MB-231 cells 
Fig. 2. Effects of thyroid hormone (T4) and NDAT on induction of PD-L1 mRNA and abundance of PD-L1 protein in MDA-MB-231 human breast cancer cells. (A) MDA-MB-231
cells were treated with varying concentrations of thyroid hormone (T4, 108 to 106 M) for 24 h. Total RNA was extracted and qPCR of PD-L1 was performed. Physiological
concentrations of T4 (107 M total, 1010 M free hormone) significantly increased cell abundance of the mRNA at 24 h. Number of independent experiments (n) for each figure
(A, B, C, D) = 3. (B) Cells were treated with T4 (107 M) in the presence or absence of NDAT (107 M tetrac-equivalent in the nanoparticulate formulation) for 24 h. Total RNA
was extracted and qPCR of PD-L1 was performed. NDAT blocked the action of T4 on PD-L1 mRNA and also reduced ‘basal’ levels of the mRNA (=PD-L1 mRNA in cells not
exposed to T4). (C) MDA-MB-231 cells were treated with T4 (108 to 106 M) for 24 h. Total protein was extracted and western blotting of PD-L1 was performed. T4 (107 M)
significantly increased cell abundance of the PD-L1 protein at 24 h. (D). Cells were treated with T4 (107 M) in the presence or absence of NDAT (107 M) for 24 h. Total protein
was extracted and western blotting of PD-L1 was carried out. NDAT prevented the action of T4 on PD-L1 protein in addition to constitutively expressed PD-L1. *p < 0.05,
**p < 0.01, ***p < 0.001, compared with control; ##p < 0.01, ###p < 0.001, compared with T4 at 107 M.
H.-Y. Lin et al. / Steroids 114 (2016) 59–67 61(11%), but statistically significant, reduction in PD-L1 mRNA
abundance in the absence of added T4 (basal PD-L1 expression).
Parallel studies were conducted to study the effect of thyroid
hormone on PD-L1 protein accumulation. MDA-MB-231 cells were
treated with different concentrations of T4 for 24 h. Total proteins
were extracted and western blot analysis of PD-L1 was conducted.
Results in Fig. 2C show that T4 at 107 M induced a 2.7-fold
increase in PD-L1 protein abundance. The T4-induced PD-L1
protein was subject to complete inhibition by NDAT. In addition,
NDAT reduced basal content of PD-L1 protein by 32% in these
breast cancer cells (Fig. 2D).3.2. Thyroid hormone induces PD-L1 expression that is inhibited by
NDAT in human colorectal cancer HCT116 cells
Human colorectal cancer HCT116 cells were treated with differ-
ent concentrations of thyroid hormone (108 to 106 M) for 24 h,
cells were harvested and total RNA was extracted. PD-L1 mRNA
was significantly induced by thyroid hormone (T4) in a concentra-
tion-dependent manner (108 to 107 M) (Fig. 3A). At 107 M total
hormone concentration, T4 increased PD-L1 mRNA abundance by
17% (p < 0.05). At 106 M, T4 induced less PD-L1 mRNA than did
the hormone at 107 M. When HCT116 cells were treated for
HCT116 cells 
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Fig. 3. Effects of thyroid hormone (T4) and NDAT on induction of PD-L1 mRNA and abundance of PD-L1 protein in HCT116 human colorectal cancer cells. (A) HCT116 cells
were treated with varying concentrations of T4 (108 to 106 M) for 24 h. Total RNA was extracted and qPCR of PD-L1 was performed. Number of independent experiments (n)
for each figure (A, B, C, D) = 3 (B). Cells were treated with T4 (107 M) in the presence or absence of NDAT (107 M) for 24 h. Total RNA was extracted and qPCR of PD-L1 was
again performed. NDAT prevented the action of T4 on PD-L1 mRNA and also reduced ‘basal’ levels of the mRNA (=PD-L1 mRNA in cells not exposed to T4). (C) HCT116 cells
were treated with T4 (108 to 106 M) for 24 h. Total protein was extracted and western blotting of PD-L1 was carried out. (D). Cells were treated with T4 (107 M) in the
presence or absence of NDAT (107 M) for 24 h. Total protein was extracted and western blotting of PD-L1 was performed. NDAT prevented the action of T4 on PD-L1 protein
in addition to constitutively expressed PD-L1. *p < 0.05, **p < 0.01, ***p < 0.001, compared with control; ##p < 0.01, ###p < 0.001, compared with T4 at 107 M.
62 H.-Y. Lin et al. / Steroids 114 (2016) 59–6724 h with 107 M T4 in the presence of NDAT (107 M), thyroid hor-
mone-induced PD-L1 mRNA accumulation was significantly
reduced (33%, p < 0.01) (Fig. 3B). Basal mRNA abundance was
decreased by 35% (p < 0.001) in the presence of NDAT.
Parallel studies of PD-L1 protein accumulation in HCT116 cells
showed that PD-L1 protein was increased by T4 on a concentra-
tion-dependent basis at 108 to 107 M (Fig. 3C). However,
106 M T4 induced less PD-L1 than did 107 M T4. NDAT (107 M)
reduced basal (no added T4) PD-L1 expression by 31% (p < 0.05)
and decreased T4-stimulated PD-L1 by 66% (p < 0.01) (Fig. 3D).The above studies were also conducted in a second human col-
orectal cancer cell line, HT-29. In these cells, PD-L1 mRNA abun-
dance increased 62% in response to T4 (107 M, p < 0.05)
(Fig. 4A). In contrast to results obtained in HCT116 cells, the supra-
physiological concentration of 106 M T4 was even more effective
in inducing expression of PD-L1 mRNA than was 107 M T4. NDAT
significantly decreased basal (30%) and T4-stimulated levels of PD-
L1 mRNA (45%) (Fig. 4B). The basal PD-L1 protein level in HT-29
colon carcinoma cells was enhanced by T4 in a concentration-
dependent manner (Fig. 4C). NDAT (107 M) reduced basal PD-L1
HT-29 cells 
(A) (B)
 PD-L1 
 GAPDH 
50 kDa - 
36 kDa - 
 PD-L1 
 GAPDH 
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Fig. 4. Effect of thyroid hormone (T4) and NDAT on induction of PD-L1 mRNA and abundance of PD-L1 protein in HT-29 human colorectal cancer cells. (A). HT-29 cells were
treated with different concentrations of T4 (108 to 106 M) for 24 h. Total RNA was extracted and qPCR of PD-L1 was performed. Number of independent experiments (n) for
each figure (A, B, C, D) = 3 (B). Cells were treated with T4 (107 M) in the presence or absence of NDAT (107 M) for 24 h. Total RNA was extracted and qPCR of PD-L1 was
performed. NDAT prevented the action of T4 on PD-L1 mRNA and also reduced ‘basal’ levels of the mRNA (=PD-L1 mRNA in cells not exposed to T4). (C) HT-29 cells were
treated with T4 (108 to 106 M) for 24 h. Total protein was extracted and Western blotting for PD-L1 was performed. (D) Cells were treated with T4 (107 M) in the presence
or absence of NDAT (107 M) for 24 h. Total protein was extracted and western blotting of PD-L1 was performed. NDAT (107 M) not only prevented basal level of PD-L1 but
also reduced T4-induced PD-L1 accumulation. *p < 0.05, **p < 0.01, ***p < 0.001, compared with control; #p < 0.05, ###p < 0.001, compared with T4 at 107 M.
H.-Y. Lin et al. / Steroids 114 (2016) 59–67 63expression by 44% (p < 0.05) and decreased T4-stimulated PD-L1 by
54% (p < 0.01) (Fig. 4D).
3.3. Activation of ERK1/2 is involved in thyroid hormone-induced
PD-L1 expression
Activation of ERK1/2 has been shown to be essential for thyroid
hormone-induced biological activities. The expression of PD-L1 is
activated ERK1/2-dependent. HCT116, HT-29 and MDA-MB-231
cells were treated with a MEK inhibitor, PD98059 (PD), 1 h priorto treatment with NDAT and thyroid hormone. Results presented
in Fig. 5 (MDA-MB-231 cells), Fig. 6 (HCT116 cells) and Fig. 7
(HT-29 cells) confirmed that thyroid hormone induced PD-L1 pro-
tein accumulation and revealed in addition that the hormonal
effect was inhibited by PD. PD also reduced the basal level of PD-
L1 accumulation and ERK1/2 activation in breast cancer cells
(MDA-MB-231 cells) and colorectal cancer cells (HCT116). Further-
more, the inhibitory effect of NDAT on T4-induced PD-L1 protein
accumulation and ERK1/2 activation were enhanced significantly
by the presence of PD (Figs. 5–7). These results indicate that
 PD-L1 
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Fig. 5. Dependence on mitogen-activated protein kinase (MAPK; phosphorylated ERK1/2) of transduction of the thyroid hormone (T4) signal on PD-L1 protein accumulation
in MDA-MB-231 breast cancer cells. MDA-MB-231 cells were treated with 107 M T4 in the presence or absence of PD (30 lM pretreatment for 1 h) and NDAT (pretreatment
for 30 min). (A). Cells were harvested 24 h later and proteins extracted for western blot analysis of PD-L1 and pERK1/2. The PD compound reduced basal levels of PD-L1
protein (B) and pERK1/2 (C), as well as T4-induced PD-L1 accumulation and ERK1/2 activation; PD also served to enhance the inhibitory effect of NDAT on T4-induced PD-L1
accumulation and ERK1/2 activation. **p < 0.01, compared with control; #p < 0.05, ###p < 0.001, compared with T4 at 107 M; §p < 0.05, §§§p < 0.001, compared with no PD
treatment. Number of independent experiments (n) for each figure (A, B, C) = 3.
64 H.-Y. Lin et al. / Steroids 114 (2016) 59–67activated ERK1/2 is involved in thyroid hormone-induced PD-L1
expression.
4. Discussion
We have previously shown that T4 at physiological concentra-
tions of free hormone is anti-apoptotic [20] and pro-angiogenic
[21]. These properties are desirable in normal cells—e.g., myocar-
diocytes, neurons—and in normal tissues, but serve undesirably
to support tumors. In the studies reported here, T4 upregulated
transcription of PD-L1 in cancer cells, serving to defend such cells
against immune system destruction. In contrast, such an action
by the hormone on nonmalignant cells would desirably defend
against destructive autoimmune processes.
A substantial number of actions of thyroid hormone on cancer
cells that support survival of such cells have been shown to be
nongenomic in origin and initiated at a thyroid hormone receptor
described on the extracellular domain of integrin avb3 [12,19].Like other integrins, avb3 is a structural protein of the plasma
membrane that is important to extracellular matrix protein-cell
interactions. The observation in the current studies that NDAT
inhibited the action of T4 on PD-L1 expression in the tumor cells
studied means that the hormone receptor on avb3 mediated the
event; that is, the inhibitory effects of NDAT on tumor cells and
dividing endothelial cells are limited to the thyroid hormone
receptor on the extracellular domain of integrin [12]. In contrast
to T4, and in part due to its action to inhibit binding of T4 at its
receptor on the integrin, NDAT has pro-apoptotic and anti-angio-
genic activities. The current in vitro studies indicate that NDAT
non-immunologically also blocks thyroid hormone actions on the
PD-L1 component of the PD-1/PD-L1 checkpoint.
In the clinical setting, the thyroid hormone axis is usually nor-
mal and thus the present studies suggest that activity of the PD-1/
PD-L1 tumor cell self-defense system is in part due to endogenous
T4. That endogenous thyroid hormone may support cancers of var-
ious types has been suggested in clinical studies of breast cancer
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Fig. 6. Dependence on MAPK-pERK1/2 of transduction of the T4 signal on PD-L1 protein accumulation in HCT116 colorectal cancer calls. HCT116 cells were treated with
107 M T4 in the presence or absence of PD (30 lM pretreatment for 1 h) and NDAT (pretreatment for 30 min). (A) Cells were harvested 24 h later and proteins extracted for
western blot analysis of PD-L1 and pERK1/2. The PD compound reduced basal levels of PD-L1 protein (B) and pERK1/2 (C), as well as T4-induced PD-L1 accumulation and
ERK1/2 activation; it also enhanced the inhibitory effect of NDAT on T4-induced PD-L1 accumulation and ERK1/2 activation. *p < 0.05, **p < 0.01, ***p < 0.001, compared with
control; #p < 0.05, ###p < 0.001, compared with T4 at 107 M; §p < 0.05, §§p < 0.01, §§§p < 0.001, compared with no PD treatment. Number of independent experiments (n) for
each figure (A, B, C) = 3.
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glioblastoma [25]. A recent observational study indicates that
maintenance of the euthyroid state with 3,5,30-triiodo-L-thyronine
(T3)—with pharmacologic elimination of T4 (=euthyroid hypothy-
roxinemia)—prolongs survival in patients with end stage cancers
[26]. In vitro studies also have shown a trophic effect of the hor-
mone on cancer cell proliferation [15,27–29]. The results presented
here raise the possibility that PD-L1-directed immunotherapy is
opposed by endogenous T4 and that such therapy might be
improved clinically by lowering of circulating T4 by pharmacologic
intervention.
Interestingly, in both of the colon cancer cell lines studied here,
NDAT also reduced PD-L1 protein content in the absence of T4.
Basal levels of PD-L1 protein in MDA-MB-231 breast cancer cells
decreased only minimally in response to NDAT. Thus, there is vari-
ation in susceptibility of the gene to regulation via the thyroid hor-
mone-NDAT receptor on avb3. In addition, the magnitude of the
response to T4 of PD-L1 mRNA and protein levels varied among
the cell lines studied. This is not surprising, given the inconsistentimportance of PD-L1 to tumor cell defense illustrated by the vari-
able clinical efficacy to-date of immunotherapy targeted at the
PD-1/PD-L1 checkpoint [5].
Immunotherapy directed at the PD-1/PD-L1 checkpoint bears a
clinical risk of induction of autoimmune destructive activity in
nonmalignant tissues [30]. Thus, alternatives to antibodies are
desirable that pharmacologically target the PD-1/PD-L1 axis specif-
ically in cancer cells. The studies reported here indicate that NDAT
may be one such non-immunologic alternative. The receptor target
of NDAT is primarily expressed by cancer cells, thus limiting expo-
sure of nonmalignant cells to disruption of the PD-1/PD-L1 check-
point by the agent. The drug also has pro-apoptotic and anti-
angiogenic activities that involve multiple mechanisms regulated
from integrin avb3 [11,12].
The present studies are the first to indicate that modulation
of PD-L1 gene expression can occur via integrin avb3. The results
raise the possibility that other small molecule ligands of the
integrin may affect the activity of the PD-1/PD-L1 checkpoint
[31].
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Fig. 7. Dependence on MAPK-pERK1/2 of transduction of the T4 signal on PD-L1 protein accumulation in HT-29 colorectal cancer cells. HT-29 cells were treated with 107 M
T4 in the presence or absence of PD (30 lM pretreatment for 1 h) and NDAT (pretreatment for 30 min). (A) Cells were harvested 24 h later and proteins extracted for Western
blot analysis of PD-L1 and pERK1/2. The PD compound reduced T4-induced PD-L1 accumulation (B) and ERK1/2 activation (C); it also enhanced the inhibitory effect of NDAT
on T4-induced ERK1/2 activation. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control; ##p < 0.01, ###p < 0.001, compared with T4 at 107 M; §p < 0.05, §§p < 0.01,
§§§p < 0.001, compared with no PD treatment. Number of independent experiments for each figure (A, B, C) = 3.
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NDAT significantly and non-immunologically suppresses
T4-induced PD-L1 gene expression in human colon and breast
cancer cells and significantly reduces cell content of PD-L1 protein.
Nonmalignant cells and normal immune system surveillance will
escape this novel effect of NDAT because normal cells, except for
rapidly dividing endothelial cells and osteoclasts, express little
avb3. In the clinical setting, the PD-L1 gene is invariably exposed
to host thyroid hormone and we speculate that host circulating
T4 supports defensive PD-1/PD-L1 checkpoint activity in tumor
cells. These results indicate that the PD-1/PD-L1 checkpoint is
subject to non-immunologic, pharmacological regulation by NDAT.Conflicts of interest
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